Precision Control of Nanoparticle Delivery with Engineered Biomimetic Protein Coronas
ACS Nano Medicine · 10.06.2026 · 1 (5) · 1290-1309
DOI: 10.1021/acsnanomed.5c00203 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano Medicine, online erschienen am 20.03.2026. Verfasst von Tanveer Shaikh und 8 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: Division of Biological Infrastructure, Office of Integrative Activities, American Cancer Society.
Abstract (Originalsprache)
Nanoparticle delivery to tumors remains inefficient, with current nanomedicines achieving only 0.7% injected dose per gram (ID/g) of tumor tissue due to uncontrolled protein corona formation that redirects nanoparticles away from target sites. We engineered biomimetic protein coronas to control nanoparticle-protein interactions and enhance tumor targeting. Competitive binding studies using NMR spectroscopy revealed that transferrin (Tf) and fibronectin (Fn) outcompete albumin (BSA) and immunoglobulin G (IgG) for 15 nm gold nanoparticle surfaces, establishing a binding hierarchy that enables predictable corona composition. Pre-coating nanoparticles with a four-protein combination (BSA+Tf+Fn+IgG) created coronas that selectively enhanced cancer cell uptake while reducing macrophage recognition in vitro. When administered to tumor-bearing mice, these engineered coronas achieved 13 ppm/g tumor accumulation—equivalent to 4% ID/g—representing 6.5-fold improvement over bare nanoparticles and 2.6-fold improvement over PEGylated formulations. Proteomics analysis of secondary coronas formed in human serum revealed that engineered nanoparticles selectively recruit transport and adhesion proteins while limiting immune recognition signatures. The pre-formed coronas maintained targeting protein retention and reduced complement binding compared to controls. Circular dichroism confirmed minimal protein structural perturbation, preserving receptor-binding functionality for active targeting. The strategy harnesses natural protein adsorption processes to create “smart” biological interfaces that simultaneously evade immune clearance and promote tumor cell recognition through multiple receptor pathways. This approach demonstrates the feasibility of treating the coron as a programmable interface, addressing delivery limitations that have hindered clinical translation of cancer nanomedicines. For Table of Contents Only
Förderung
- Division of Biological Infrastructure
- Office of Integrative Activities
- American Cancer Society
- Division of Chemical, Bioengineering, Environmental, and Transport Systems
- National Science Foundation
Zitieren
APA
Shaikh, T., Amarasekara, D. L., Hulugalla, K., Toragall, V. B., Garrigues, R. J., Mayatt, R. S., Werfel, T., Zeczycki, T. N., & Fitzkee, N. C. (2026). Precision Control of Nanoparticle Delivery with Engineered Biomimetic Protein Coronas. ACS Nano Medicine, 1(5), 1290-1309. https://doi.org/10.1021/acsnanomed.5c00203
Vancouver
Shaikh T, Amarasekara DL, Hulugalla K, Toragall VB, Garrigues RJ, Mayatt RS, et al. Precision Control of Nanoparticle Delivery with Engineered Biomimetic Protein Coronas. ACS Nano Medicine. 2026;1(5):1290-1309. doi:10.1021/acsnanomed.5c00203
BibTeX
@article{Shaikh2026,
author = {Shaikh, Tanveer and Amarasekara, Dhanush L. and Hulugalla, Kenneth and Toragall, Veeresh B. and Garrigues, Ryan J. and Mayatt, Railey S. and Werfel, Thomas and Zeczycki, Tonya N. and Fitzkee, Nicholas C.},
title = {Precision Control of Nanoparticle Delivery with Engineered Biomimetic Protein Coronas},
journal = {ACS Nano Medicine},
year = {2026},
volume = {1},
number = {5},
pages = {1290--1309},
doi = {10.1021/acsnanomed.5c00203}
}
EUVIMED